Summary The in vitro deamination, cytotoxicity, cellular drug uptake, distribution and cellular pharmacology in HL-60 cells of N'-hexadecyl-l-p-D-arabinofuranosykcytosine (NHAC), a lipophilic derivative of arabinofuranosylcytosine (ara-C), were studied. Compared with ara-C, NHAC in liposomal formulations was highly resistant to deamination, resulting in levels of formation of arabinofuranosyluracil 42 and ten times lower in plasma and liver microsomes respectively. The cytotoxicity of NHAC was independent of both the nucleoside transporter mechanism and the deoxycytidine (dCyd) kinase activity as demonstrated by coincubating NHAC with dipyridamole and/or dCyd. In ara C-resistant HL-60 cells NHAC was still cytotoxic, requiring drug concentration only 1.6 times higher than sensitive cells. Uptake of NHAC was six times higher and was not inhibited by dipyridamole. The pharmacokinetics of NHAC revealed that its intracellular half-life is 4.8 times longer than that of ara-C. Ara-CTP formation and incorporation into DNA was up to 25-50 times lower than that of ara-C and contributed only marginally to the cytotoxic effects of NHAC. These results indicate that, because of the significantly increased stability, the transporter-independent uptake and the dCyd-kinase-independent cytotoxicity, NHAC might be active in ara-C-resistant cells.
I-P-i-Arabinofuranosylcytosine (ara-C) is one of the most effective agents in the treatment of acute myelogenous leukaemia (Keating et al., 1982; Plunkett and Gandhi, 1993) . However, its usefulness is limited by its rapid deamination to the biologically inactive metabolite l-p-D-arabinofuranosyluracil (ara-U) (Ho and Frei, 1971) . Thus, to be therapeutically effective, ara-C must be administered either continuously for 5 days (Frei et al., 1969) or as high-dose regimens up to 3 g m2 (Momparler, 1974) . In order to avoid or delay the deamination of ara-C in vivo, a large number of NAderivatives of ara-C have been synthesised (Wempen et al., 1968; Kanai and Ichino, 1974; Rosowsky et al., 1982) or ara-C was used in combination therapies with deaminase inhibitors such as tetrahydrouridine (Kreis et al., 1991) or zebularine (Driscoll et al., 1991) . Lipophilic ara-C derivatives modified with long-chain fatty acids show strong anti-tumour activity in murine tumour models (Aoshima et al., 1976; Kataoka and Sakurai, 1980; Tsuruo et al., 1980) . A related 5'-substituted liponucleotide, cytarabine ocfosfate, has recently been approved for clinical use in Japan (Houlihan et al., 1995) . In a previous study we demonstrated that Nacyl derivatives of ara-C incorporated into the membranes of small unilamellar liposomes are active against murine L1210 leukaemia and B16 melanoma cells at concentrations 2-4 times lower than ara-C (Rubas et al., 1986) . However, resistance of the N'-acyl derivative N'-oleyl-l-p-i-arabinofuranosylcytosine to enzymatic deamination to ara-U was only partially achieved and suggested to be still insufficient in a phase I/II study (Schwendener et al., 1989) . For this reason we synthesised the N'-alkyl-ara-C derivative N-hexadecyl-l-pf D-arabinofuranosylcytosine (NHAC) (Schwendener and Schott, 1992) . This compound has greater tumour-inhibitory effects than ara-C in the L1210 tumour model at molar drug concentrations 16 times lower. NHAC also exerts a strong cytotoxic effect at single dose schedules, suggesting a longlasting drug effect.
A major reason for treatment failure in leukaemia patients is ara-C resistance. Possible mechanisms of ara-C resistance that have been proposed include low levels of deoxycytidine kinase (Chu and Fisher, 1965) , increased catabolism by cytidine deaminase (Steuart and Burke, 1971 ) and a decreased number of nucleoside transport sites (Wiley et al., 1982) . The cellular uptake of ara-C is achieved by transporter mediated facilitated diffusion (Plagemann et al., 1978) . Because of the lipophilicity of NHAC we postulate a transporter-independent uptake mechanism as well as altered behaviour in cellular pharmacokinetics.
In the present study, we investigated the deamination kinetics of NHAC and ara-C in human plasma and mouse liver microsomes. Furthermore, we evaluated the properties of NHAC compared with ara-C by studying in vitro its cytotoxicity in the human myeloid leukaemia cell line HL-60 and, in ara-C-resistant HL-60/ara-C cells, the cellular uptake, the intracellular drug distribution and pharmacokinetics, the rate of ara-CP formation and incorporation into DNA.
Materials and methods

Drugs
Ara-C, dipyridamole and 2'-deoxycytidine (dCyd) were purchased from Sigma (Buchs, Switzerland). [5-3H-]Ara-C (30 Ci mmol i) and custom-synthesised [5-3HNHAC (5.1 Ci mmol') were purchased from Amersham (Amersham, UK). For all incubations, ara-C was dissolved in phosphate-buffered saline (PBS; 8 mM sodium phosphate, 1.5 mM potassium dihydrogen phosphate, 0.14 M sodium chloride, 2.6 mM potassium chloride) with trace amounts of [53Hlara-C. NHAC was given in a liposomal formulation as described in the Liposome preparation section. NHAC was synthesised as previously described (Schwendener and Schott, 1992 The ara-C-resistant HL-60 cells (HL-60/ara-C) were a kind gift from Dr Studzinski, UMD-New Jersey Medical School, Newark, NJ, USA (Kolla and Studzinski, 1994) . This HL-60/ ara-C sublime has been isolated and characterised by Bhalla et al. (1984) . The Ocells ml-'). Then the cells were exposed to various concentrations (0-200 9AM) of ara-C, NHAC or empty liposomes in the presence or absence of 20,UM dipyridamole and/or 209AM dCyd for 24 h at 37C (5% carbon dioxide). Dipyridamole and/or dCyd were added 5 min before drug exposure. After incubation the medium was removed, the cells washed once and resuspended in fresh, serum-free RPMI-1640 medium. The cell survival fractions were determined with the 344,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT) dye reduction assay as described by Mosmann (1983) . All experiments were repeated four times. Accordingly, the cytotoxic effects of ara-C and liposomal NHAC against HL-60/ara-C-resistant cells Figure I shows the kinetics of deamination of liposomal NHAC and ara-C in human plasma (Figure la) and mouse liver microsomes (Figure lb) . NHAC was almost completly resistant to deamination in plasma, resulting in a 42-fold reduction in ara-U formation after 4 h incubation. Expressed as a percentage, 84% of ara-C was deaminated to ara-U, whereas only 2% of NHAC was deaminated to ara-U. In the concentration-dependent study using freshly prepared mouse liver microsomes, NHAC was deaminated to ara-U at a slower rate and at concentrations 5-10 times lower than ara-C. These results demonstrate that NHAC is highly resistant to deamination. Cytotoxicitv in HL-60 cells The cytotoxicity of NHAC and ara-C in HL-60 cells in the MTT dye reduction assay after a continuous 24 h incubation is shown in Figure 2a . (Figure 2d ). Dipyridamole is a well-characterised nucleoside transporter-blocking agent (King et al., 1984) . As shown in Figure 2b , the cytotoxicity of ara-C was strongly reduced by dipyridamole (IC20=215± 131M and IC50>40011M), but not with NHAC (IC20= 9.3± 1.3gM and IC = 48.9 ± 3.1 g1M), indicating a nucleoside transporterindependent uptake mechanism for NHAC (see also Figure  4 ). dCyd is the physiological substrate of dCyd-kinase and a Celdu pharmaogy Of N-dgc_aC DH Horber et al 959 competitive inhibitor of ara-C phosphorylation (Coleman et al., 1975) . As shown in Figure 2c , the cytotoxicity of ara-C was significantly decreased by the addition of 20 iM dCyd S min before drug exposure. Thus, the IC2! value for ara-C increased from 0.9 ± 0.1 1AM to 186.3 ± 4.0 tLM when the cells were pretreated with dCyd. In contrast, the cytotoxic effect of NHAC was not affected by dCyd, indicating that the mode of action of NHAC is independent to a great extent of the phosphorylation pathway. The combination of dipyridamole plus dCyd led to a further decrease in the cytotoxic effect of ara-C. As shown in Figure 2d . an ICO value for ara-C was therefore not reached at drug concentrations below 200 1AM. In contrast, the cytotoxicity of NHAC was not influenced by pretreating the HL-60 cells with dipynrdamole plus dCyd, resulting in an IC50 value of 46.9 ± 3.4 1M, which is identical to the IC50 value of the NHAC treatment without additives (Figure 2a) or the treatment with dipyridamole or dCyd alone (Figure 2b and c) .
Cvtotoxicitv in ara-C-resistant HL-60 cells (HL-60/ara-C) Figure 3 shows the concentration-dependent cytotoxic effects of ara-C and liposomal NHAC on the HL-60/ara-C-resistant cells. However, it should be noted that direct comparison of the HL-60 and HL-60/ara-C cell lines is difficult because of their different growth characteristics. The doubling time was found to be 30 h for the HL-60 cells and 22 h for the HL-60/ara-C cells. NHAC was more cytotoxic than ara-C to HL-60/ara-C cells in the concentration range up to 200 1AM. However, compared with the ara-C-sensitive HL-60 cells the cytotoxic effect of NHAC was slightly reduced, requiring 77.0± 2.9 1M to reach the ICO as compared with 47. Figure 4 summarises the cellular uptake of ara-C and liposomal NHAC in HL-60 cells in the presence and absence of the nucleoside transporter-blocking agent dipyridamole. The uptake of ara-C was slightly higher than that of NHAC at low drug concentrations up to 101AM, however it was highly sensitive to dipyridamole. Thus, by adding dipyridamole 5 min before drug exposure, the uptake of ara-C decreased by a factor of 2.5-28 depending on the drug concentration. The uptake of NHAC, in contrast, was not blocked by dipyridamole, resulting in a 4-to 15-fold higher drug accumulation over the whole concentration range of 1-200 1M, and in a 1.5-to 6-fold higher uptake compared with ara-C alone in the range 20-200 1M. In contrast to NHAC, the uptake of ara-C revealed typical Michaelis-Menten kinetics, reaching saturation at 40-60 1AM. These results provide evidence that the uptake of lipophilic NHAC is not dependent on the nucleoside transport mechanism and the number of transport sites per cell. Table I summarises the parameters of the intracellular pharmacokinetics of ara-C, NHAC and ara-CTP determined by incubating the cells for various periods in drug-free medium after 2 h drug exposure. All three compounds followed firstorder kinetics during incubation periods of up to 3.5 h. The intracellular half-life for ara-C was 1.55 h, whereas the halflife for NHAC was 4.8 times longer, indicating a depot effect of the drug in the cellular membranes. The half-life for ara-CTP formed from NHAC was 1.8 times longer than that from ara-C. The longer half-life of ara-CTP originating from NHAC may be caused by the slow dealkylation of NHAC to ara-C and its subsequent phosphorylation to ara-CTP. The AUC of NHAC was 5.9 times that of ara-C, whereas the AUC of ara-CTP formed from ara-C was 3.6 times greater than formed from NHAC. Phosphorylated metabolites of NHAC (e.g. NHAC-triphosphate) were not detected by the method used for the measurement of ara-CTP.
Cellular drug uptake
Cellular pharmacokinetics
Ara-CTP formation
The concentration-dependent formation of ara-CTP from ara-C and liposomal NHAC is shown in Figure 5 . Significantly higher amounts of ara-CTP were formed from ara-C, reaching levels 5-90-times higher than those formed from NHAC. In contrast to NHAC, ara-C again revealed Drug concentration (gm)
Fugwe 4 Uptake of ara-C and NHAC in HL-60 cells. Cells were exposed to various concentrations of ara-C or NHAC for 3 h at 3TC (5% carbon dioxide) in the presence or absence of the nucleside transporter-blocking agent dipyridamole (20 pM). Dipyridamole was added 5 min before drug exposure. Ara-C (U), ara-C plus dipyridamole (-), NHAC (0), NHAC plus dipyridamole (0); Symbols = mean from three separate experiments; bars = s.d. Where no error bars are seen, they are than the size of the symbols.
Michaelis-Menten kinetics, reaching saturation at 40 M, whereas ara-CTP formation from NHAC increased with linear kinetics, not reaching saturation below 200 pM. The molar ratios of ara-CTP formed by ara-C and NHAC were for 1 Lm and 209AM drug concentration 90 and 39 respectively. In the concentration range of 1-60 9M, which is cytotoxic to HL-60 cells (Figure 2a) , the amounts of ara-CUP formed from NHAC were 90 to 16 times lower. These low ara-CTP concentrations are not likely to be sufficient to contribute sniicantly to the cytotoxic activity of NHAC, as shown in the MTT dye reduction assays (Figure 2a and c).
Incorporation into DNA
As shown in Table II , incorporation of metabolites into DNA after incubation with ara-C for up to 6 h was independent of the incubation time and on average 25 times higher than after NHAC incubation. After 24 h however, the incorporation into DNA of metabolites orginating from ara-C was rdud, which can be explained by the higher cytotoxic effect on the HL-60 lls of ara-C at the concentration of 2#zm (Figure 2a ).
In the present study, the cellular pharmacology of a liposomal preparation of NHAC, a new lipophilic alkyl derivative of ara-C, was investigated. Since the N4-acyl-ara-C derivatives, including N-behenoyl-ara-C, have been consided as prodrugs which are actvted through metaboEsation to ara-C followed by phosphorylation to ara-CTP (Ueda et al., 1983) , we first studied whether the mechanism of cytotoxicity of the N4-alkyl-ara-C derivative NHAC is the sam as that of other cytidine analogue The effects of ara-C on DNA synthesis and thus its cytotoxic activity are gnrally explained by two mecaisms. In the first, the cytotoxic effect is produced by inhibition of DNA polymrase by ara-CP through enzyme competition with endogenous deoxy-CTP (Furth and Cohen, 1968; Momparler et al., 1990) . The incorporation of ara-CTP into DNA as a strnd brek-inducing nucleotide is the second mechanism and does not exclude the inhibition of DNA polymerase. Kufe and collaborators (Major et al., 1981; Kufe et al., 1984) have demonstrated in their studies that the extent of ara-C incorporation into DNA is the most powerful predictor of cytotoxicity.
Our results with NHAC indicate, however, that although small amounts of ara-C and ara-CP are derived from NHAC ( Figure 5 ), these low concentrations of ara-CP and DNA-incorporated metabolites (Tables I and II) . (Steuart and Burke 1971; Tattersall et al., 1974) .
The cdlular uptake of NHAC could not be saturated at drug concentrations up to 200 gm and was again, in contrast to ara-C, independent of the number of nucleoside transport sites, suggesting that drug uptake is achieved by a passive diffusion process mainly resulting from the lipophilic properties of NHAC rather than by a transporter-mediated, active mechanism. Thus, the uptake of NHAC in leukaemia cells might be explained by fusion of liposomes with the cellular membranes, by direct transfer of NHAC from the liposomes to the cell membranes or by liposome phagocytosis.
Probably the most significant advantage of NHAC over ara-C consists in its greatly improved stability against deamination, which might be responsible for the difference in cellular pharmacological properties such as the longer intracellular half-life (Table I) . These properties allow NHAC to be administered at lower doses than an-C to obtain better anti-tumour effects in vivo (Schwendener and Schott, 1992) . The possibility of producing large batches of sterile and stable drug-containing liposomes (Schwendener, 1992) provides the opportunity to enter cinical studies with NHAC. Owing to the high lipophilicity of the NHAC molecule, it is essential to incorporate NHAC into liposomes in order to obtain a physiological drug formulation. The liposomes themselves and their size have no significant effect on the uptake of NHAC in vitro (data not shown). The release of NHAC from the hposomes and its interactions with blood components have been studied in detail and the results will be reported separately (Horber et al., 1995) .
In conclusion, our study strongly suggests that NHAC is able to overcome ara-C resistance by circumvention of the major reasons for treatment failure among leukaemia patients. Thus, NHAC is cytotoxic independently of the nucoside transport mechanism and the dCyd kinase activity in HL-60 cells and it still retains its activity in ara-C-resistant HL-60/ara-C cells. Furthermore, the cellular uptake of liposomal NHAC is higher than that of ara-C and independent of the nucleoside transport hanism. Long-chain alkylation of the amino group of ara-C provides excellent protection against deamination and inactivation to ara-U. Although the exact mechanism of action has not yet been elucidated and further pharmacological studies are required. nevertheless it seems to be obvious that the mechanism of cytotoxicity of NHAC is very different from that of ara-C or the M-acyl-ara-C derivatives.
